# Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma

> **NCT00181220** · PHASE1 · WITHDRAWN · sponsor: **Johns Hopkins University**

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** valproic acid

## Key facts

- **NCT ID:** NCT00181220
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left JHU and is not able to be reached for updates
- **Last updated:** 2020-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181220, "Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00181220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*